Document Detail

Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.
MedLine Citation:
PMID:  16502765     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: The present study was conducted to assess the effect of food on the bioavailability of fenofibric acid from a new tablet formulation containing fenofibrate nanoparticles. METHODS: In this 3-way crossover study, 45 subjects received in a random order one 145 mg fenofibrate tablet under high-fat fed (HFF), low-fat fed (LFF) or fasting (reference) conditions. Plasma concentrations of fenofibric acid were determined up to 120 hours post-dose. Comparisons were made between test (HFF and LFF) and reference conditions (fasting). RESULTS: Very close values of pharmacokinetic parameters were obtained following the three diffiferent regimens. The 90% confidence intervals (CI) for the ratio of geometric means of HIFF versus fasting condition were (1.018-1.088) for AUCinfinity, (1.020-1.090) for AUCt and (0.963-1.054) for Cmax with point estimate:s of 1.052, 1.054 and 1.007, respectively. The 90% CI for the geometric means of LFF versus fasting condition were (0.978-1.046) for AUGinfinity, (0.981-1.047) for AUCt and (0.964-1.055) for Cmax with point estimates of 1.012, 1.013 and 1.009, respectively. They all fall within the required limits for bioequivalence (0.80-1.25). A slightly prolonged tmax was observed following HFF conditions (4.3 +/- 1.9 hours, versus 3.6 +/- 1.2 hours and 2.3 +/- 0.7 hours under LFF and fasting conditions, respectively), without any effect on mean Cmax. CONCLUSION: The peak and overall exposures from the new 145 mg fenofibrate tablet were not affected by food. Therefore, this new fenofibrate tablet may be taken without regard to the timing of meals.
R Sauron; M Wilkins; V Jessent; A Dubois; C Maillot; A Weil
Related Documents :
23106405 - Microbiological properties and biogenic amines of whole pike-perch (sander lucioperca, ...
19928485 - Providing calorie information on fast-food restaurant menu boards: consumer views.
12885395 - Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporat...
8742945 - A physicochemical basis for the effect of food on the absolute oral bioavailability of ...
23554735 - Prevalence of intestinal parasitic infections in certified food-handlers working in foo...
16929635 - Treatment of high-strength pet food wastewater using two-stage membrane bioreactors.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  International journal of clinical pharmacology and therapeutics     Volume:  44     ISSN:  0946-1965     ISO Abbreviation:  Int J Clin Pharmacol Ther     Publication Date:  2006 Feb 
Date Detail:
Created Date:  2006-02-28     Completed Date:  2006-04-27     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9423309     Medline TA:  Int J Clin Pharmacol Ther     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  64-70     Citation Subset:  IM    
Department of Clinical Pharmacokinetics, Laboratoires Fournier S.A., 50, Rue de Dijon, 21121 Daix, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antilipemic Agents / administration & dosage,  blood,  pharmacokinetics*
Area Under Curve
Biological Availability
Cross-Over Studies
Dietary Fats / administration & dosage
Dose-Response Relationship, Drug
Fasting / blood
Food-Drug Interactions*
Procetofen / administration & dosage,  blood,  pharmacokinetics*
Reference Values
Reg. No./Substance:
0/Antilipemic Agents; 0/Dietary Fats; 0/Tablets; 49562-28-9/Procetofen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Placental transfer of antibiotics administered to the mother: a review.
Next Document:  Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined ...